|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
EP0279862B1
(en)
|
1986-08-28 |
1993-11-03 |
Teijin Limited |
Cytocidal antibody complex and process for its preparation
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
JP5004390B2
(ja)
|
1999-08-23 |
2012-08-22 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
新規ｂ７−４分子およびその用途
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
|
EP1286700A2
(en)
|
2000-06-01 |
2003-03-05 |
Universite Catholique De Louvain |
Tumor activated prodrug compounds
|
|
EP1320599A2
(en)
|
2000-06-28 |
2003-06-25 |
Genetics Institute, LLC |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
WO2002030460A2
(en)
|
2000-10-09 |
2002-04-18 |
Isis Innovation Ltd. |
Therapeutic antibodies
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
WO2002079499A1
(en)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US20040109855A1
(en)
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
US7449300B2
(en)
|
2002-11-21 |
2008-11-11 |
Mayo Foundation For Medical Education And Research |
Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
|
|
DK1810026T3
(en)
|
2004-10-06 |
2018-07-16 |
Mayo Found Medical Education & Res |
B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
AU2006284651C1
(en)
|
2005-08-31 |
2013-09-12 |
The Regents Of The University Of California |
Cellular libraries of peptide sequences (CLiPS) and methods of using the same
|
|
JP2009529522A
(ja)
|
2006-03-10 |
2009-08-20 |
ディアト |
酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
|
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
EP2124998B8
(en)
|
2006-12-27 |
2015-05-06 |
The Johns Hopkins University |
Methods for detecting inflammation and auto-immune diseases
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US8062852B2
(en)
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
MX2011005691A
(es)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
WO2010077643A1
(en)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Masking ligands for reversible inhibition of multivalent compounds
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
|
US20110280877A1
(en)
|
2010-05-11 |
2011-11-17 |
Koji Tamada |
Inhibition of B7-H1/CD80 interaction and uses thereof
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
EP2882844B1
(en)
|
2012-08-10 |
2018-10-03 |
Cytomx Therapeutics Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
WO2014074852A1
(en)
|
2012-11-09 |
2014-05-15 |
President And Fellows Of Harvard College |
Compositions and methods for modulating an immune response
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CN105008918A
(zh)
|
2013-01-04 |
2015-10-28 |
西托姆克斯治疗公司 |
用于检测生物系统中的蛋白酶活性的组合物和方法
|
|
US20150344577A1
(en)
|
2013-01-11 |
2015-12-03 |
Dingfu Biotarget Co., Ltd |
Agents for treating tumors, use and method thereof
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
|
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
US20150071910A1
(en)
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
BR112015023120A2
(pt)
|
2013-03-15 |
2017-11-21 |
Genentech Inc |
método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
TN2015000444A1
(en)
|
2013-06-03 |
2017-04-06 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
EP3293275B1
(en)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
FR3008408B1
(fr)
|
2013-07-11 |
2018-03-09 |
Mc Saf |
Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
US10966998B2
(en)
|
2013-09-05 |
2021-04-06 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
|
WO2015038538A1
(en)
|
2013-09-10 |
2015-03-19 |
Medimmune, Llc |
Compositions and methods for treating sepsis
|
|
WO2015036499A1
(en)
|
2013-09-11 |
2015-03-19 |
Medimmune Limited |
Anti-b7-h1 antibodies for treating tumors
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
MY175472A
(en)
|
2013-09-27 |
2020-06-29 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
EP3060581A4
(en)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
WO2015069697A2
(en)
|
2013-11-05 |
2015-05-14 |
Nkt Therapeutics Inc. |
Combination therapy
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
PL3763387T3
(pl)
|
2013-11-25 |
2024-07-29 |
Famewave Ltd |
Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu
|
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
US10241115B2
(en)
|
2013-12-10 |
2019-03-26 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
|
|
EP3079699A4
(en)
|
2013-12-11 |
2017-07-19 |
Glaxosmithkline LLC |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
WO2015092393A2
(en)
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Human targets
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
JP2017507900A
(ja)
|
2013-12-17 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
NZ759969A
(en)
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
US10835595B2
(en)
|
2014-01-06 |
2020-11-17 |
The Trustees Of The University Of Pennsylvania |
PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
PL3094351T3
(pl)
|
2014-01-15 |
2022-06-27 |
Kadmon Corporation, Llc |
Środki immunomodulujące
|
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
BR112016014952A2
(pt)
|
2014-02-10 |
2017-09-19 |
Merck Patent Gmbh |
Inibição direcionada de tgfbeta
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US9987258B2
(en)
|
2014-04-06 |
2018-06-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase as a modulator of PDL1 expression and activity
|
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
PL3142751T3
(pl)
|
2014-05-13 |
2019-12-31 |
Medimmune Limited |
Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
KR20150135148A
(ko)
|
2014-05-23 |
2015-12-02 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
EP3149043A1
(en)
|
2014-05-29 |
2017-04-05 |
Medimmune Limited |
Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
|
|
JP6666905B2
(ja)
|
2014-05-29 |
2020-03-18 |
スプリング バイオサイエンス コーポレーション |
Ｐｄ−ｌ１抗体及びその使用
|
|
JP6652557B2
(ja)
|
2014-05-30 |
2020-02-26 |
ヴェンタナ メディカル システムズ， インク． |
Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
US10449227B2
(en)
|
2014-06-27 |
2019-10-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
CN121243402A
(zh)
|
2014-07-09 |
2026-01-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1组合
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
US10280223B2
(en)
|
2014-07-09 |
2019-05-07 |
Nippon Zenyaku Kogyo Co., Ltd. |
Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
CA2955612C
(en)
|
2014-07-18 |
2022-05-17 |
Advaxis, Inc. |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
|
KR102476226B1
(ko)
|
2014-08-05 |
2022-12-12 |
아폴로믹스 인코포레이티드 |
항-pd-l1 항체
|
|
KR101940430B1
(ko)
|
2014-08-07 |
2019-01-18 |
가꼬우호우징 효고 이카다이가쿠 |
Il-18과 분자 표적 항체를 병용하는 암 치료약
|
|
WO2016023875A1
(en)
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
|
|
EP3070102A1
(en)
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
MX2017002875A
(es)
|
2014-09-08 |
2017-05-30 |
Celgene Corp |
Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
|
|
CN107074952B
(zh)
|
2014-09-30 |
2021-04-09 |
英特维特国际股份有限公司 |
结合犬pd-l1的pd-l1抗体
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
CN108064166A
(zh)
|
2014-10-23 |
2018-05-22 |
戊瑞治疗有限公司 |
Slamf1拮抗剂及其用途
|
|
KR20230128139A
(ko)
|
2014-10-24 |
2023-09-01 |
아스트라제네카 아베 |
조합물
|
|
EP3212670B1
(en)
|
2014-10-29 |
2020-12-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
WO2016075174A1
(en)
|
2014-11-11 |
2016-05-19 |
Medimmune Limited |
Therapeutic combinations for treating neoplasia
|
|
EP3220951A1
(en)
|
2014-11-17 |
2017-09-27 |
MedImmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
CN105777906B
(zh)
|
2014-12-19 |
2019-04-23 |
苏州丁孚靶点生物技术有限公司 |
抗pd-l1全人抗体及其应用
|
|
US10849862B2
(en)
|
2014-12-26 |
2020-12-01 |
Theravalues Corporation |
Formulation of curcumin and anti-PD-1 antibody
|
|
PL3240801T3
(pl)
|
2014-12-31 |
2021-06-14 |
Checkmate Pharmaceuticals, Inc. |
Skojarzona immunoterapia nowotworów
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
CA2973720A1
(en)
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
TWI632160B
(zh)
|
2015-01-16 |
2018-08-11 |
中央研究院 |
具有標的部分及效應部分的分子構建體
|
|
WO2016123285A1
(en)
|
2015-01-29 |
2016-08-04 |
The Trustees Of The University Of Pennsylvania |
Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
|
|
ES2791950T3
(es)
|
2015-02-03 |
2020-11-06 |
Ventana Med Syst Inc |
Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
WO2016154412A2
(en)
|
2015-03-26 |
2016-09-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
|
|
WO2016160792A1
(en)
|
2015-03-30 |
2016-10-06 |
Stcube & Co., Inc. |
Antibodies specific to glycosylated pd-l1 and methods of use thereof
|
|
WO2016160966A1
(en)
|
2015-03-30 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of treating renal cell cancer
|
|
US20180085398A1
(en)
|
2015-03-30 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of treating cancer
|
|
US20180071340A1
(en)
|
2015-03-30 |
2018-03-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of treating multiple myeloma
|
|
US20180078650A1
(en)
|
2015-03-30 |
2018-03-22 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of treating acute myeloid leukemia
|
|
WO2016160973A1
(en)
|
2015-03-30 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of treating cancer
|
|
US20180079814A1
(en)
|
2015-04-01 |
2018-03-22 |
Medimmune Limited |
Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
WO2016170040A1
(en)
|
2015-04-23 |
2016-10-27 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1
|
|
WO2016175275A1
(ja)
|
2015-04-30 |
2016-11-03 |
国立大学法人京都大学 |
Ｐｄ－ｌ１（ｃｄ２７４）の異常を指標としたｐｄ－１／ｐｄ－ｌ１阻害剤の治療効果予測方法
|
|
ES2835866T5
(es)
|
2015-05-12 |
2024-12-02 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
|
US10945994B2
(en)
|
2015-05-14 |
2021-03-16 |
Pfizer Inc. |
Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
AR105618A1
(es)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
CN106243225B
(zh)
|
2015-06-11 |
2021-01-19 |
智翔（上海）医药科技有限公司 |
新型抗-pd-l1抗体
|
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
US10532056B2
(en)
|
2015-06-29 |
2020-01-14 |
Verastem, Inc. |
Therapeutic compositions, combinations, and methods of use
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
EP3322731B1
(en)
|
2015-07-14 |
2021-01-13 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
|
|
US20170021019A1
(en)
|
2015-07-22 |
2017-01-26 |
Matthew Zibelman |
COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
US20180296561A1
(en)
|
2015-10-07 |
2018-10-18 |
The University Of North Carolina At Chapel Hill |
The Methods For Treatment Of Tumors
|
|
WO2017066557A1
(en)
|
2015-10-15 |
2017-04-20 |
Duke University |
Combination treatment
|
|
CN108290931A
(zh)
|
2015-10-30 |
2018-07-17 |
阿菲博迪公司 |
对pd-l1具有亲和力的新的多肽
|
|
US10364280B2
(en)
|
2015-10-30 |
2019-07-30 |
Affibody Ab |
Polypeptide
|
|
CA3004804A1
(en)
|
2015-11-17 |
2017-05-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
|
|
US20180346571A1
(en)
|
2015-11-17 |
2018-12-06 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
|
WO2017087851A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Genentech, Inc. |
Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
|
|
LT3386541T
(lt)
|
2015-12-07 |
2020-10-26 |
Merck Patent Gmbh |
Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
|
|
JP6994240B2
(ja)
|
2015-12-07 |
2022-02-04 |
国立大学法人京都大学 |
Ｐｄ－１シグナル阻害剤の併用療法
|
|
CN105461808B
(zh)
|
2015-12-24 |
2019-03-19 |
长春金赛药业股份有限公司 |
单克隆抗体及其应用
|
|
EP3400442A4
(en)
|
2016-01-08 |
2019-06-26 |
Biothera, Inc. |
BETA-GLUCAN IMMUNOTHERAPIES WITH INFLUENCE OF THE MICRO ENVIRONMENT OF THE IMMUNE SYSTEM
|
|
KR20180098671A
(ko)
|
2016-01-11 |
2018-09-04 |
인히브릭스, 인크. |
다가 및 다중특이적 ox40-결합 융합 단백질
|
|
WO2017136562A2
(en)
|
2016-02-02 |
2017-08-10 |
Kadmon Corporation, Llc |
Bispecific binding proteins for pd-l1 and kdr
|
|
US11421028B2
(en)
|
2016-02-06 |
2022-08-23 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
RU2693661C2
(ru)
|
2016-03-04 |
2019-07-03 |
Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. |
Антитело против pdl-1, его фармацевтическая композиция и применение
|
|
WO2017161154A2
(en)
|
2016-03-16 |
2017-09-21 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
|
|
CA3007135A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
|
ES2883297T3
(es)
|
2016-03-29 |
2021-12-07 |
Stcube Inc |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
SG11201808626WA
(en)
|
2016-04-07 |
2018-10-30 |
Chemocentryx Inc |
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|
|
KR20190017735A
(ko)
|
2016-04-07 |
2019-02-20 |
캔써 리서치 테크놀로지 리미티드 |
종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
|
|
EP3440113A1
(en)
|
2016-04-08 |
2019-02-13 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
WO2017189433A1
(en)
|
2016-04-25 |
2017-11-02 |
Medimmune, Llc |
Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
|
|
RU2018142711A
(ru)
|
2016-05-04 |
2020-06-04 |
Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. |
Средство для целенаправленного воздействия на дельта-опиоидный рецептор для молекулярной визуализации и иммунотерапии рака
|
|
EA201892522A1
(ru)
|
2016-05-05 |
2019-05-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
SG11201809336QA
(en)
|
2016-05-09 |
2018-11-29 |
Igm Biosciences Inc |
Anti-pd-l1 antibodies
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
US11414491B2
(en)
|
2016-05-18 |
2022-08-16 |
Mayo Foundation For Medical Education And Research |
Targeting PD-L1 on tumor cells
|
|
LT3458053T
(lt)
|
2016-05-20 |
2022-02-25 |
Biohaven Pharmaceutical Holding Company Ltd. |
Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
|
|
CA3025391A1
(en)
|
2016-05-26 |
2017-11-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for cancer treatment
|
|
WO2017205801A1
(en)
|
2016-05-27 |
2017-11-30 |
Takeda Pharmaceutical Company Limited |
Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
|
|
CN107459578B
(zh)
|
2016-05-31 |
2021-11-26 |
泰州迈博太科药业有限公司 |
一种靶向cd47与pd-l1的双功能融合蛋白
|
|
JP7016323B2
(ja)
|
2016-06-01 |
2022-02-21 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
US20190106494A1
(en)
|
2016-06-13 |
2019-04-11 |
Askgene Pharma Inc. |
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
US10077308B2
(en)
|
2016-06-13 |
2018-09-18 |
Askgene Pharma Inc. |
PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
|
|
UA126905C2
(uk)
|
2016-06-13 |
2023-02-22 |
Ай-Маб Байофарма Юес Лімітед |
Антитіло до pd-l1 та його застосування
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018005682A2
(en)
|
2016-06-29 |
2018-01-04 |
Checkpoint Therapeutics, Inc. |
Pd-l1-specific antibodies and methods of using the same
|
|
MA45595A
(fr)
|
2016-07-07 |
2019-05-15 |
Iovance Biotherapeutics Inc |
Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
|
|
CN106243223B
(zh)
|
2016-07-28 |
2019-03-05 |
北京百特美博生物科技有限公司 |
抗人pdl1抗体及其用途
|
|
RU2721582C1
(ru)
|
2016-08-05 |
2020-05-20 |
И-Байолоджикс Инк. |
Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
WO2018054940A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
|
WO2018057506A1
(en)
|
2016-09-20 |
2018-03-29 |
Medimmune, Llc |
Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy
|
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
|
CN106478819B
(zh)
|
2016-10-27 |
2018-12-07 |
常州费洛斯药业科技有限公司 |
一种针对pd-l1的单克隆抗体或抗体片段
|
|
WO2018080812A1
(en)
|
2016-10-30 |
2018-05-03 |
Henlix, Inc. |
Anti-pd-l1 antibodies and variants
|
|
WO2018089780A1
(en)
|
2016-11-11 |
2018-05-17 |
Medimmune, Llc |
Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
|
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
EP4649966A3
(en)
|
2016-12-01 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
EP3551659A1
(en)
|
2016-12-08 |
2019-10-16 |
Eli Lilly and Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
|
EP3551663A1
(en)
|
2016-12-12 |
2019-10-16 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
CN106978400A
(zh)
|
2016-12-13 |
2017-07-25 |
无锡傲锐东源生物科技有限公司 |
抗pd‑l1蛋白单克隆抗体及其用途
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
CN110072553B
(zh)
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
|
CN110337448B
(zh)
|
2016-12-23 |
2023-08-08 |
瑞美德生物医药科技有限公司 |
使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
|
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
|
US11377497B2
(en)
|
2017-01-23 |
2022-07-05 |
Suzhou Alphamab Co., Ltd. |
PD-L1 binding polypeptide or composite
|
|
CN106699891B
(zh)
|
2017-01-25 |
2019-04-09 |
北京天广实生物技术股份有限公司 |
一种抗pd-l1抗体、其药物组合物及其用途
|
|
KR20230145547A
(ko)
|
2017-02-16 |
2023-10-17 |
메디뮨 엘엘씨 |
방광암의 항-pd-l1 항체 치료
|
|
EP3583127B1
(en)
|
2017-02-16 |
2024-11-20 |
Ying Zhang |
Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof
|
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
|
DK3592769T3
(da)
|
2017-03-09 |
2024-08-12 |
Genmab As |
Antistoffer mod pd-l1
|
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
US20200095323A1
(en)
|
2017-03-20 |
2020-03-26 |
The General Hospital Corporation |
MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
|
|
US20200148785A1
(en)
|
2017-03-29 |
2020-05-14 |
Glycotope (GmbH) |
Pd-l1 and ta-muc1 antibodies
|
|
WO2018178123A1
(en)
|
2017-03-29 |
2018-10-04 |
Glycotope Gmbh |
BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
|
|
RU2765997C2
(ru)
|
2017-03-30 |
2022-02-07 |
Мерк Патент Гмбх |
Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
|
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
CN110914302A
(zh)
*
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
CN107973854B
(zh)
|
2017-12-11 |
2021-05-04 |
苏州银河生物医药有限公司 |
Pdl1单克隆抗体及其应用
|
|
CN108250296B
(zh)
|
2018-01-17 |
2020-07-07 |
长春金赛药业有限责任公司 |
全人源抗人pd-l1单克隆抗体及其应用
|
|
CN108276492B
(zh)
|
2018-01-31 |
2021-12-14 |
中国药科大学 |
抗pd－l1单克隆抗体及其应用
|